Background: Carbapenem-resistant Enterobacterales (CRE) are a critical-priority pathogen group on the World Health Organization's 2024 list. Most clinically significant carbapenem resistance in Enterobacterales is mediated by acquired carbapenemases, chiefly KPC, NDM, VIM, IMP and OXA-48- like enzymes. Accurate and timely laboratory detection of these enzymes directly shapes antimicrobial therapy, infection prevention and surveillance. Aim: To review the phenotypic, immunochromatographic, molecular and mass-spectrometric methods available to clinical laboratories for detecting carbapenemase-producing Enterobacterales (CPE), and to propose a practical, tiered testing algorithm. Review Results: The CLSI-endorsed modified carbapenem inactivation method (mCIM) offers sensitivity of about 97–99% and specificity of 99–100% at a reagent cost near one US dollar, but needs an overnight incubation. When paired with the EDTA-modified method (eCIM), it also separates metallo-β-lactamases from serine carbapenemases. Colorimetric tests such as Carba NP give results within about 2 hours but miss a proportion of OXA-48-like producers. Multiplex lateral flow immunoassays identify the five major enzyme families in about 15 minutes with reported sensitivity and specificity above 95%. Real-time PCR platforms such as Xpert Carba-R deliver gene-level results within about an hour but detect only targeted genes. Conclusion: No single method is sufficient for every laboratory. A tiered approach that screens with a low-cost phenotypic test, classifies the enzyme with an immunochromatographic or molecular assay, and refers discordant isolates for sequencing gives the best balance of accuracy, speed and cost.
No takes yet. Share an insight, caveat, or question.
Yasser H Babaier (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: